

Olivier Chinot, Pu-Ph

List of Publications by Citations

Source: <https://exaly.com/author-pdf/630657/olivier-chinot-pu-ph-publications-by-citations.pdf>

Version: 2024-04-28

This document has been generated based on the publications and citations recorded by exaly.com. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

116
papers

7,315
citations

43
h-index

84
g-index

123
ext. papers

8,650
ext. citations

6.2
avg, IF

5.05
L-index

#	Paper	IF	Citations
116	Radiotherapy for glioblastoma in the elderly. <i>New England Journal of Medicine</i> , 2007 , 356, 1527-35	59.2	602
115	European Association for Neuro-Oncology (EANO) guideline on the diagnosis and treatment of adult astrocytic and oligodendroglial gliomas. <i>Lancet Oncology</i> , 2017 , 18, e315-e329	21.7	599
114	Short-Course Radiation plus Temozolomide in Elderly Patients with Glioblastoma. <i>New England Journal of Medicine</i> , 2017 , 376, 1027-1037	59.2	525
113	EANO guideline for the diagnosis and treatment of anaplastic gliomas and glioblastoma. <i>Lancet Oncology</i> , 2014 , 15, e395-403	21.7	498
112	Temozolomide chemotherapy versus radiotherapy in high-risk low-grade glioma (EORTC 22033-26033): a randomised, open-label, phase 3 intergroup study. <i>Lancet Oncology</i> , 2016 , 17, 1521-1532	21.7	294
111	PAI-1 and EGFR expression in adult glioma tumors: toward a molecular prognostic classification. <i>International Journal of Radiation Oncology Biology Physics</i> , 2002 , 52, 592-8	4	286
110	Absence of IDH mutation identifies a novel radiologic and molecular subtype of WHO grade II gliomas with dismal prognosis. <i>Acta Neuropathologica</i> , 2010 , 120, 719-29	14.3	233
109	Recurrent mutations of MYD88 and TBL1XR1 in primary central nervous system lymphomas. <i>Clinical Cancer Research</i> , 2012 , 18, 5203-11	12.9	170
108	Temozolomide in elderly patients with newly diagnosed glioblastoma and poor performance status: an ANOCEF phase II trial. <i>Journal of Clinical Oncology</i> , 2011 , 29, 3050-5	2.2	167
107	Comparative assessment of 5 methods (methylation-specific polymerase chain reaction, MethyLight, pyrosequencing, methylation-sensitive high-resolution melting, and immunohistochemistry) to analyze O6-methylguanine-DNA-methyltransferase in a series of 100 glioblastoma patients. <i>Cancer</i> , 2012 , 118, 4201-11	6.4	149
106	Intracerebral administration of CpG oligonucleotide for patients with recurrent glioblastoma: a phase II study. <i>Neuro-Oncology</i> , 2010 , 12, 401-8	1	147
105	A Phase II randomized study of galunisertib monotherapy or galunisertib plus lomustine compared with lomustine monotherapy in patients with recurrent glioblastoma. <i>Neuro-Oncology</i> , 2016 , 18, 1146-56 ¹		135
104	Oncological patterns of care and outcome for 952 patients with newly diagnosed glioblastoma in 2004. <i>Neuro-Oncology</i> , 2010 , 12, 725-35	1	130
103	Methotrexate and temozolomide versus methotrexate, procarbazine, vincristine, and cytarabine for primary CNS lymphoma in an elderly population: an intergroup ANOCEF-GOELAMS randomised phase 2 trial. <i>Lancet Haematology</i> , 2015 , 2, e251-9	14.6	115
102	Temozolomide and methotrexate for primary central nervous system lymphoma in the elderly. <i>Journal of Neuro-Oncology</i> , 2007 , 85, 207-11	4.8	113
101	Neutralization of adrenomedullin inhibits the growth of human glioblastoma cell lines in vitro and suppresses tumor xenograft growth in vivo. <i>American Journal of Pathology</i> , 2002 , 160, 1279-92	5.8	109
100	Long-term tumor control and functional outcome in patients with cavernous sinus meningiomas treated by radiotherapy with or without previous surgery: is there an alternative to aggressive tumor removal?. <i>Neurosurgery</i> , 2001 , 48, 285-94; discussion 294-6	3.2	109

99	Does Valproic Acid or Levetiracetam Improve Survival in Glioblastoma? A Pooled Analysis of Prospective Clinical Trials in Newly Diagnosed Glioblastoma. <i>Journal of Clinical Oncology</i> , 2016 , 34, 731-9 ^{2.2}	108
98	Effects of adrenomedullin on endothelial cells in the multistep process of angiogenesis: involvement of CRLR/RAMP2 and CRLR/RAMP3 receptors. <i>International Journal of Cancer</i> , 2004 , 108, 797-804	7.5 105
97	Multicentric French study on adult intracranial ependymomas: prognostic factors analysis and therapeutic considerations from a cohort of 152 patients. <i>Brain</i> , 2007 , 130, 1338-49	11.2 100
96	Radiotherapy or Autologous Stem-Cell Transplantation for Primary CNS Lymphoma in Patients 60 Years of Age and Younger: Results of the Intergroup ANOCEF-GOELAMS Randomized Phase II PRECIS Study. <i>Journal of Clinical Oncology</i> , 2019 , 37, 823-833	2.2 92
95	Use of proton magnetic resonance spectroscopy of the brain to differentiate gliomatosis cerebri from low-grade glioma. <i>Journal of Neurosurgery</i> , 2003 , 98, 269-76	3.2 87
94	Primary CNS lymphoma at first relapse/progression: characteristics, management, and outcome of 256 patients from the French LOC network. <i>Neuro-Oncology</i> , 2016 , 18, 1297-303	1 80
93	Health-related quality of life in patients with high-risk low-grade glioma (EORTC 22033-26033): a randomised, open-label, phase 3 intergroup study. <i>Lancet Oncology</i> , 2016 , 17, 1533-1542	21.7 77
92	Prognostic impact of the 2016 WHO classification of diffuse gliomas in the French POLA cohort. <i>Acta Neuropathologica</i> , 2016 , 132, 625-34	14.3 72
91	Prognostic impact of O6-methylguanine-DNA methyltransferase silencing in patients with recurrent glioblastoma multiforme who undergo surgery and carmustine wafer implantation: a prospective patient cohort. <i>Cancer</i> , 2009 , 115, 4783-94	6.4 67
90	Polysialic acid neural cell adhesion molecule (PSA-NCAM) is an adverse prognosis factor in glioblastoma, and regulates olig2 expression in glioma cell lines. <i>BMC Cancer</i> , 2010 , 10, 91	4.8 66
89	FDG-PET predicts survival in recurrent high-grade gliomas treated with bevacizumab and irinotecan. <i>Neuro-Oncology</i> , 2012 , 14, 649-57	1 64
88	Adult intracranial WHO grade II ependymomas: long-term outcome and prognostic factor analysis in a series of 114 patients. <i>Neuro-Oncology</i> , 2010 , 12, 976-84	1 59
87	Promoter Methylation Cutoff with Safety Margin for Selecting Glioblastoma Patients into Trials Omitting Temozolomide: A Pooled Analysis of Four Clinical Trials. <i>Clinical Cancer Research</i> , 2019 , 25, 1809-1816 ^{12.0}	59
86	Noninvasive diagnostic assessment of brain tumors using combined in vivo MR imaging and spectroscopy. <i>Magnetic Resonance in Medicine</i> , 2006 , 55, 1236-45	4.4 58
85	The CareGiver Oncology Quality of Life questionnaire (CarGOQoL): development and validation of an instrument to measure the quality of life of the caregivers of patients with cancer. <i>European Journal of Cancer</i> , 2012 , 48, 904-11	7.5 57
84	Contrast enhancement in 1p/19q-codeleted anaplastic oligodendrogliomas is associated with 9p loss, genomic instability, and angiogenic gene expression. <i>Neuro-Oncology</i> , 2014 , 16, 662-70	1 55
83	IDH mutation status impact on in vivo hypoxia biomarkers expression: new insights from a clinical, nuclear imaging and immunohistochemical study in 33 glioma patients. <i>Journal of Neuro-Oncology</i> , 2011 , 105, 591-600	4.8 55
82	The DNA methylome of DDR genes and benefit from RT or TMZ in IDH mutant low-grade glioma treated in EORTC 22033. <i>Acta Neuropathologica</i> , 2018 , 135, 601-615	14.3 54

81	High expression of cathepsin B and plasminogen activator inhibitor type-1 are strong predictors of survival in glioblastomas. <i>Acta Neuropathologica</i> , 2009 , 118, 745-54	14.3	54
80	Supratentorial ependymomas: prognostic factors and outcome analysis in a retrospective series of 46 adult patients. <i>Cancer</i> , 2008 , 113, 175-85	6.4	51
79	Targeting adrenomedullin receptors with systemic delivery of neutralizing antibodies inhibits tumor angiogenesis and suppresses growth of human tumor xenografts in mice. <i>FASEB Journal</i> , 2009 , 23, 3424-35	0.9	50
78	Prognostic impact of CD133 mRNA expression in 48 glioblastoma patients treated with concomitant radiochemotherapy: a prospective patient cohort at a single institution. <i>Annals of Surgical Oncology</i> , 2011 , 18, 2937-45	3.1	49
77	Primary CNS lymphoma in patients younger than 60: can whole-brain radiotherapy be deferred?. <i>Journal of Neuro-Oncology</i> , 2011 , 104, 323-30	4.8	48
76	Intracerebral injection of CpG oligonucleotide for patients with de novo glioblastoma-A phase II multicentric, randomised study. <i>European Journal of Cancer</i> , 2017 , 73, 30-37	7.5	47
75	Ex vivo cultures of glioblastoma in three-dimensional hydrogel maintain the original tumor growth behavior and are suitable for preclinical drug and radiation sensitivity screening. <i>Experimental Cell Research</i> , 2014 , 321, 99-108	4.2	45
74	Association of matrix metalloproteinase 2 plasma level with response and survival in patients treated with bevacizumab for recurrent high-grade glioma. <i>Neuro-Oncology</i> , 2014 , 16, 392-9	1	43
73	Independent prognostic value of pre-treatment 18-FDG-PET in high-grade gliomas. <i>Journal of Neuro-Oncology</i> , 2012 , 107, 527-35	4.8	41
72	Validation of postoperative residual contrast-enhancing tumor volume as an independent prognostic factor for overall survival in newly diagnosed glioblastoma. <i>Neuro-Oncology</i> , 2018 , 20, 1240-1250	1	39
71	Everolimus and Octreotide for Patients with Recurrent Meningioma: Results from the Phase II CEVOREM Trial. <i>Clinical Cancer Research</i> , 2020 , 26, 552-557	12.9	38
70	Recurrence of glioblastoma after radio-chemotherapy is associated with an angiogenic switch to the CXCL12-CXCR4 pathway. <i>Oncotarget</i> , 2015 , 6, 11664-75	3.3	38
69	MMP2 and MMP9 as candidate biomarkers to monitor bevacizumab therapy in high-grade glioma. <i>Neuro-Oncology</i> , 2015 , 17, 1174-6	1	37
68	Up-front temozolomide in elderly patients with glioblastoma. <i>Journal of Neuro-Oncology</i> , 2010 , 99, 89-94.	4.8	35
67	Histological and MR correlations in Gliomatosis cerebri. <i>Journal of Neuro-Oncology</i> , 2002 , 59, 249-59	4.8	35
66	Chemotherapy for the treatment of oligodendroglial tumors. <i>Seminars in Oncology</i> , 2001 , 28, 13-8	5.5	35
65	Rituximab-Lenalidomide (REVRI) in Relapse or Refractory Primary Central Nervous System (PCNSL) or Vitreo Retinal Lymphoma (PVRL): Results of a "Proof of Concept" Phase II Study of the French LOC Network. <i>Blood</i> , 2016 , 128, 785-785	2.2	35
64	An ANOCEF genomic and transcriptomic microarray study of the response to radiotherapy or to alkylating first-line chemotherapy in glioblastoma patients. <i>Molecular Cancer</i> , 2010 , 9, 234	42.1	34

63	Validation of the high-performance of pyrosequencing for clinical MGMT testing on a cohort of glioblastoma patients from a prospective dedicated multicentric trial. <i>Oncotarget</i> , 2016 , 7, 61916-61929	3.3	34
62	Prognostic value of cytosolic thymidine kinase activity as a marker of proliferation in breast cancer. <i>International Journal of Cancer</i> , 1995 , 61, 7-12	7.5	32
61	Oncological patterns of care and outcomes for 265 elderly patients with newly diagnosed glioblastoma in France. <i>Neurosurgical Review</i> , 2014 , 37, 415-23; discussion 423-4	3.9	31
60	MMP2 and MMP9 serum levels are associated with favorable outcome in patients with inflammatory breast cancer treated with bevacizumab-based neoadjuvant chemotherapy in the BEVERLY-2 study. <i>Oncotarget</i> , 2016 , 7, 18531-40	3.3	31
59	Combined treatment by octreotide and everolimus: Octreotide enhances inhibitory effect of everolimus in aggressive meningiomas. <i>Journal of Neuro-Oncology</i> , 2015 , 124, 33-43	4.8	28
58	Octreotide therapy in meningiomas: in vitro study, clinical correlation, and literature review. <i>Journal of Neurosurgery</i> , 2017 , 127, 660-669	3.2	27
57	Links between private habits, psychological stress and brain cancer: a case-control pilot study in France. <i>Journal of Neuro-Oncology</i> , 2011 , 103, 307-16	4.8	27
56	Infratentorial ependymomas: prognostic factors and outcome analysis in a multi-center retrospective series of 106 adult patients. <i>Acta Neurochirurgica</i> , 2009 , 151, 947-60	3	27
55	Molecular genetics of adult grade II gliomas: towards a comprehensive tumor classification system. <i>Journal of Neuro-Oncology</i> , 2012 , 110, 205-13	4.8	26
54	Allelic loss of 9p21.3 is a prognostic factor in 1p/19q codeleted anaplastic gliomas. <i>Neurology</i> , 2015 , 85, 1325-31	6.5	25
53	Genesis and biology of vestibular schwannomas. <i>Progress in Neurological Surgery</i> , 2008 , 21, 24-31	1.4	24
52	SNP array analysis reveals novel genomic abnormalities including copy neutral loss of heterozygosity in anaplastic oligodendrogliomas. <i>PLoS ONE</i> , 2012 , 7, e45950	3.7	23
51	MALDI imaging and in-source decay for top-down characterization of glioblastoma. <i>Proteomics</i> , 2014 , 14, 1290-301	4.8	22
50	End-binding 1 protein overexpression correlates with glioblastoma progression and sensitizes to Vinca-alkaloids in vitro and in vivo. <i>Oncotarget</i> , 2014 , 5, 12769-87	3.3	22
49	Reirradiation and concomitant metronomic temozolomide: an efficient combination for local control in medulloblastoma disease?. <i>Journal of Pediatric Hematology/Oncology</i> , 2011 , 33, 600-4	1.2	21
48	Early evaluation of tumoral response to antiangiogenic therapy by arterial spin labeling perfusion magnetic resonance imaging and susceptibility weighted imaging in a patient with recurrent glioblastoma receiving bevacizumab. <i>Journal of Clinical Oncology</i> , 2011 , 29, e308-11	2.2	21
47	Biomarker and Histopathology Evaluation of Patients with Recurrent Glioblastoma Treated with Galunisertib, Lomustine, or the Combination of Galunisertib and Lomustine. <i>International Journal of Molecular Sciences</i> , 2017 , 18,	6.3	20
46	Symptom clusters in newly diagnosed glioma patients: which symptom clusters are independently associated with functioning and global health status?. <i>Neuro-Oncology</i> , 2019 , 21, 1447-1457	1	19

45	Biological heterogeneity of ER-positive breast cancers in the post-menopausal population. <i>International Journal of Cancer</i> , 1994 , 59, 17-9	7.5	19
44	Deletions of chromosomes 1p and 19q are detectable on frozen smears of gliomas by FISH: usefulness for stereotactic biopsies. <i>Journal of Neuro-Oncology</i> , 2004 , 68, 141-9	4.8	18
43	Whole Brain Radiotherapy (WBRT) Versus Intensive Chemotherapy with Haematopoietic Stem Cell Rescue (IC + HCR) for Primary Central Nervous System Lymphoma (PCNSL) in Young Patients: An Intergroup Anocéf-Goelams Randomized Phase II Trial (PRECIS). <i>Blood</i> , 2016 , 128, 782-782	2.2	17
42	Patterns of response and relapse in primary CNS lymphomas after first-line chemotherapy: imaging analysis of the ANOCEF-GOELAMS prospective randomized trial. <i>Neuro-Oncology</i> , 2017 , 19, 422-429	1	17
41	Coping strategies and quality of life: a longitudinal study of high-grade glioma patient-caregiver dyads. <i>Health and Quality of Life Outcomes</i> , 2018 , 16, 157	3	16
40	Epidermal growth factor receptor in glioblastomas: correlation between gene copy number and protein expression. <i>Human Pathology</i> , 2010 , 41, 815-23	3.7	16
39	Divergent effect of TGFbeta1 on growth and proteolytic modulation of human prostatic-cancer cell lines. <i>International Journal of Cancer</i> , 1996 , 66, 796-801	7.5	16
38	Dyadic effects of coping strategies, time perspectives, and personality on the quality of life of cancer patients and their caregivers. <i>Psycho-Oncology</i> , 2018 , 27, 590-599	3.9	15
37	Recurrent extraneural sonic hedgehog medulloblastoma exhibiting sustained response to vismodegib and temozolomide monotherapies and inter-metastatic molecular heterogeneity at progression. <i>Oncotarget</i> , 2018 , 9, 10175-10183	3.3	15
36	Molecular heterogeneity of glioblastomas: does location matter?. <i>Oncotarget</i> , 2016 , 7, 902-13	3.3	15
35	Adrenomedullin expression and regulation in human glioblastoma, cultured human glioblastoma cell lines and pilocytic astrocytoma. <i>European Journal of Cancer</i> , 2011 , 47, 1727-35	7.5	14
34	Predictive biomarkers investigated in glioblastoma. <i>Expert Review of Molecular Diagnostics</i> , 2014 , 14, 883-93	3.8	13
33	Assessing the quality of life among caregivers of patients with gliomas. <i>Neuro-Oncology Practice</i> , 2014 , 1, 191-197	2.2	13
32	Post-chemoradiation volumetric response predicts survival in newly diagnosed glioblastoma treated with radiation, temozolomide, and bevacizumab or placebo. <i>Neuro-Oncology</i> , 2018 , 20, 1525-1535	1	12
31	Monitoring therapeutic monoclonal antibodies in brain tumor. <i>MAbs</i> , 2014 , 6, 1385-93	6.6	12
30	Pasireotide is more effective than octreotide, alone or combined with everolimus on human meningioma. <i>Oncotarget</i> , 2017 , 8, 55361-55373	3.3	12
29	Adrenomedullin blockade induces regression of tumor neovessels through interference with vascular endothelial-cadherin signalling. <i>Oncotarget</i> , 2015 , 6, 7536-53	3.3	12
28	Prognostic value of health-related quality of life for death risk stratification in patients with unresectable glioblastoma. <i>Cancer Medicine</i> , 2016 , 5, 1753-64	4.8	12

27	The added value of health-related quality of life as a prognostic indicator of overall survival and progression-free survival in glioma patients: a meta-analysis based on individual patient data from randomised controlled trials. <i>European Journal of Cancer</i> , 2019 , 116, 190-198	7.5	11
26	FDG-PET to predict different patterns of progression in multicentric glioblastoma: a case report. <i>Journal of Neuro-Oncology</i> , 2008 , 90, 47-51	4.8	11
25	Clinical validation of the CE-IVD marked Therascreen MGMT kit in a cohort of glioblastoma patients. <i>Cancer Biomarkers</i> , 2017 , 20, 435-441	3.8	10
24	Occupational and environmental risk factors for brain cancer: a pilot case-control study in France. <i>Presse Medicale</i> , 2010 , 39, e35-44	2.2	10
23	Differential scanning calorimetry of plasma in glioblastoma: toward a new prognostic / monitoring tool. <i>Oncotarget</i> , 2018 , 9, 9391-9399	3.3	10
22	Tubulin isoforms identified in the brain by MALDI in-source decay. <i>Journal of Proteomics</i> , 2013 , 79, 172-93.9	9	
21	Relationship between magnetic resonance imaging characteristics and plasmatic levels of MMP2 and MMP9 in patients with recurrent high-grade gliomas treated by Bevacizumab and Irinotecan. <i>Journal of Neuro-Oncology</i> , 2017 , 132, 433-437	4.8	8
20	Domains of quality of life freely expressed by cancer patients and their caregivers: contribution of the SEIQoL. <i>Health and Quality of Life Outcomes</i> , 2017 , 15, 99	3	8
19	Treatment of aggressive recurrent meningiomas: spinning towards peptide receptor radionuclide therapy. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 2019 , 46, 537-538	8.8	8
18	Changes in PLGF and MET-HGF expressions in paired initial and recurrent glioblastoma. <i>Journal of Neuro-Oncology</i> , 2016 , 130, 431-437	4.8	7
17	An ANOCEF genomic and transcriptomic microarray study of the response to irinotecan and bevacizumab in recurrent glioblastomas. <i>BioMed Research International</i> , 2014 , 2014, 282815	3	6
16	High-grade glioma in elderly patients: can the oncogeriatrician help?. <i>Clinical Interventions in Aging</i> , 2013 , 8, 1617-24	4	5
15	Absence of R140Q mutation of isocitrate dehydrogenase 2 in gliomas and breast cancers. <i>Oncology Letters</i> , 2010 , 1, 883-884	2.6	5
14	Neuro-radiological characteristics of adult diffuse grade II and III insular gliomas classified according to WHO 2016. <i>Journal of Neuro-Oncology</i> , 2019 , 142, 511-520	4.8	5
13	Evidence-based management of adult patients with diffuse glioma - AuthorsReply. <i>Lancet Oncology, The</i> , 2017 , 18, e430-e431	21.7	4
12	Leptomeningeal Gliomatosis: A Single Institution Study of 31 Patients. <i>Anticancer Research</i> , 2019 , 39, 1035-1041	2.3	3
11	Relationships Between Dose Intensity, Toxicity, and Outcome in Patients with Oligodendroglial Tumors Treated with the PCV Regimen. <i>Anticancer Research</i> , 2015 , 35, 2901-8	2.3	3
10	Bing-Neel syndrome: a cerebral Richter syndrome?. <i>Neurology India</i> , 2014 , 62, 229-30	0.7	2

9	A multicenter prospective observational study of the conformity of temozolomide prescriptions in France. <i>Pharmacoepidemiology and Drug Safety</i> , 2012 , 21, 828-34	2.6	2
8	The French LOC Network for Primary CNS Lymphoma (PCNSL) Patients: What Can We Learn from a Large National Database?. <i>Blood</i> , 2016 , 128, 926-926	2.2	2
7	Clustering based on unsupervised binary trees to define subgroups of cancer patients according to symptom severity in cancer. <i>Quality of Life Research</i> , 2018 , 27, 555-565	3.7	1
6	Analyse phñomñologique interprñtative auprñ de conjoints de patients prñsentant une tumeur cfñbrale maligne. Soins de support et rñle des aidants. <i>Annales Medico-Psychologiques</i> , 2018 , 176, 448-455	0.2	1
5	ATNT-10DOES VALPROIC ACID IMPROVE SURVIVAL IN GLIOBLASTOMA? A META-ANALYSIS OF RANDOMIZED TRIALS IN NEWLY DIAGNOSED GLIOBLASTOMA. <i>Neuro-Oncology</i> , 2015 , 17, v12.2-v12	1	1
4	Association of carcinoid tumor and low grade glioma. <i>World Journal of Surgical Oncology</i> , 2012 , 10, 236	3.4	1
3	A case of cerebello-thalamo-cortical diaschisis. <i>Clinical Nuclear Medicine</i> , 2008 , 33, 717-8	1.7	1
2	Adult H3K27M mutated thalamic glioma patients display a better prognosis than unmutated patients.. <i>Journal of Neuro-Oncology</i> , 2022 , 156, 615	4.8	1
1	The creation and implementation of advanced practice nursing in France: Experiences from the field. <i>International Nursing Review</i> , 2021 , 68, 412-419	3.5	1